Results 21 to 30 of 34 matches
Category 5 - DIAGNOSTIC IMAGING SERVICES
61577 - Additional Information
Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
Category 5 - DIAGNOSTIC IMAGING SERVICES
61598 - Additional Information
Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R).
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
Category 5 - DIAGNOSTIC IMAGING SERVICES
61604 - Additional Information
Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R).
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
Category 5 - DIAGNOSTIC IMAGING SERVICES
61610 - Additional Information
Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes (R).
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
Category 5 - DIAGNOSTIC IMAGING SERVICES
61612 - Additional Information
Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if:
(a) the cancer is a typically FDG-avid cancer; and
(b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patient
Applicable once per cancer diagnosis (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.17, IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61614 - Additional Information
Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.17, IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61620 - Additional Information
Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61622 - Additional Information
Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61628 - Additional Information
Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61632 - Additional Information
Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Results 21 to 30 of 34 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change